Portola Announces Oral Presentation of Data on PRT4445, Factor Xa Inhibitor Antidote, at ATVB Scientific Sessions
SOUTH SAN FRANCISCO, CA--(Marketwired - Apr 30, 2013) - Portola Pharmaceuticals, Inc. today announced that data from a Phase 1 single ascending dose study of PRT4445, a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery, will be presented in an oral session at the upcoming Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB) 2013 Scientific Sessions, which is taking place in Lake Buena Vista, Fla. from May 1-3.
Details of the oral presentation follow:
Abstract title: "Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Pharmacokinetic and Pharmacodynamic Study of PRT064445, a Universal Antidote for Factor Xa Inhibitors" (Abstract #91)
Session: I B-Blood Coagulation and Antithrombotic Therapy
Presentation date/time: Wednesday, May 1, 2013 at 11:45 a.m. Eastern Time
Location: Southern Hemisphere II, the Dolphin Hotel, Lake Buena Vista, Fla.
Presenter: Michael Kitt, M.D., Portola Pharmaceuticals
About Portola Pharmaceuticals, Inc.
Portola is a biopharmaceutical company focused on the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who currently have limited or no approved treatment options. Portola's current development-stage portfolio consists of three compounds discovered through its internal research efforts and one discovered by Portola scientists during their time at a prior company.
Portola's two lead programs address significant unmet medical needs in the area of thrombosis, or blood clots. Portola's lead compound Betrixaban is a novel oral once-daily inhibitor of Factor Xa in Phase 3 development for extended duration prophylaxis, or preventive treatment, of a form of thrombosis known as venous thromboembolism, or VTE, in acute medically ill patients. Currently, there is no anticoagulant approved for extended duration VTE prophylaxis in this population.
Portola's second lead development candidate, PRT4445, is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. Portola has entered into a collaboration agreement with Bristol-Myers Squibb Company and Pfizer Inc. and a collaboration agreement with Bayer Pharma AG and Janssen Pharmaceuticals, Inc. to study PRT4445 with ELIQUIS® and XARELTO®, respectively, in Portola's Phase 2 study. Portola retains full, worldwide commercial rights with respect to PRT4445.
Portola's third product candidate, PRT2070, is an orally available kinase inhibitor being developed for hematologic, or blood, cancers and inflammatory disorders. PRT2070 inhibits spleen tyrosine kinase, or Syk, and janus kinases, or JAK, enzymes that regulate important signaling pathways. Subject to regulatory approval, Portola plans to initiate a Phase 1/2 clinical study of PRT2070 in 2013 in patients with B-cell hematologic cancers who have failed or relapsed on existing marketed therapies or products in development, including patients with identified mutations. Portola's fourth product candidate, PRT2607, is a highly selective inhibitor of Syk that Portola has partnered with Biogen Idec for certain indications.
